Nektar Therapeutics (NASDAQ: NKTR) is -28.60% lower on its value in year-to-date trading and has touched a low of $0.43 and a high of $1.93 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NKTR stock was last observed hovering at around $0.63 in the last trading session, with the day’s gains setting it 0.03%.
Currently trading at $0.66, the stock is 4.99% and -13.53% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.07 million and changing 6.09% at the moment leaves the stock -37.94% off its SMA200. NKTR registered -49.70% loss for a year compared to 6-month loss of -54.21%. The firm has a 50-day simple moving average (SMA 50) of $0.7682 and a 200-day simple moving average (SMA200) of $1.07.
The stock witnessed a -23.12% gain in the last 1 month and extending the period to 3 months gives it a -26.55%, and is 9.95% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.18% over the week and 12.55% over the month.
Nektar Therapeutics (NKTR) has around 61 employees, a market worth around $123.57M and $98.43M in sales. Profit margin for the company is -120.86%. Distance from 52-week low is 53.70% and -65.56% from its 52-week high. The company has generated returns on investments over the last 12 months (-50.58%).
with sales reaching $15.92M over the same period.The EPS is expected to shrink by -13.65% this year, but quarterly earnings will post -35.13% year-over-year. Quarterly sales are estimated to shrink -26.45% in year-over-year returns.
Nektar Therapeutics (NKTR) Top Institutional Holders
184.0 institutions hold shares in Nektar Therapeutics (NKTR), with institutional investors hold 72.81% of the company’s shares. The shares outstanding are 185.78M, and float is at 179.37M with Short Float at 4.33%. Institutions hold 71.89% of the Float.
The top institutional shareholder in the company is DEEP TRACK CAPITAL, LP with over 17.88 million shares valued at $22.17 million. The investor’s holdings represent 8.5599% of the NKTR Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 15.16 million shares valued at $18.79 million to account for 7.2575 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 12.97 million shares representing 6.2097% and valued at over $16.08 million, while SAMLYN CAPITAL, LLC holds 4.529 of the shares totaling 9.46 million with a market value of $11.73 million.
Nektar Therapeutics (NKTR) Insider Activity
The most recent transaction is an insider sale by Zalevsky Jonathan, the company’s Chief R&D Officer. SEC filings show that Zalevsky Jonathan sold 10,300 shares of the company’s common stock on Feb 19 ’25 at a price of $1.01 per share for a total of $10403.0. Following the sale, the insider now owns 0.32 million shares.
Nektar Therapeutics disclosed in a document filed with the SEC on Feb 19 ’25 that Wilson Mark Andrew (Chief Legal Officer) sold a total of 11,040 shares of the company’s common stock. The trade occurred on Feb 19 ’25 and was made at $1.01 per share for $11150.0. Following the transaction, the insider now directly holds 0.32 million shares of the NKTR stock.
Still, SEC filings show that on Feb 19 ’25, ROBIN HOWARD W (President & CEO) disposed off 23,774 shares at an average price of $1.01 for $24012.0. The insider now directly holds 1,086,901 shares of Nektar Therapeutics (NKTR).
